Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases

US7514423B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Stefan Schafer · Aachen, DE
• Wolfgang Linz · Mainz, DE
• Markus Bleich · Brechen, DE
• Jochen Huber · Mittelbiberach, DE

Key dates

• Filing date: Apr 1, 2005
• Grant date: Apr 7, 2009
• Expiry date: Nov 11, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention discloses and claims the use of vasopeptidase inhibitors of formula (II)for the treatment of nephropathy in non-diabetic patients.